Drug Database
NI

NIK-127

✓ Approved

Kowa · Small Molecule · Small Molecule

What is NIK-127?

NIK-127 is a small molecule developed by Kowa. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyKowa
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Kowa

Therapeutic Indications

NIK-127 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersDiarrhoea✓ Approved

Related Research Articles

PubMedAmerican journal of cancer research2026-07-17

METTL14/IGF2BP-mediated m6A methylation of circSLIT2 promotes malignant phenotypes of glioblastoma via the miR-127-5p/SH3GLB1 axis.

Wu Lijun L, Jin Menghao M, Chen Liangchong L, Jiang Yang Y et al.

Glioblastoma is a highly aggressive and lethal brain tumor that typically originates from glial cells, characterized by rapid growth and resistance to treatment, leading to poor patient prognosis. This study investigates the role and mechanism of the newly discovered circular RNA CircSLIT2 in the malignant progression of glioblastoma. We found that circSLIT2 is significantly overexpressed in glioblastoma cell lines and promotes the proliferation, migration, and invasion of glioblastoma cells by regulating miR-127-5p and upregulating SH3GLB1 expression. In vitro experiments demonstrated that the overexpression of circSLIT2 enhanced cell viability, while treatment with miR-127-5p mimics significantly inhibited this effect. Additionally, we confirmed that CircSLIT2 sponges miR-127-5p, reducing its negative regulation of SH3GLB1 and thereby maintaining SH3GLB1's stable expression. We further revealed the critical roles of METTL14 and IGF2BP1 in the m6A methylation and stability of CircSLIT2. Finally, in a nude mouse model, mice with CircSLIT2 overexpression exhibited significantly larger tumor volumes and shorter survival times, providing further evidence of the important role of CircSLIT2 in glioblastoma development and progression. These findings suggest that CircSLIT2 could serve as a potential molecular target, offering new insights for glioblastoma treatment.

PMID 42465010
Read full article →
PubMedScientific reports2026-07-17

Cone beam computed tomography evaluation of the temporomandibular joint in patients with and without temporomandibular dysfunctions.

Mohsen Ahmed Maher AM, Al-Balaa Maher M, Al-Nasri Akram Mohammed Ali AMA, Khalifa Mayar MohammedSadiq MM et al.

analyze the morphometric and morphological variations of the temporomandibular joints (TMJs) using cone-beam computed tomography (CBCT) in individuals with and without temporomandibular disorders (TMD), and to explore their relationship with various sagittal and vertical skeletal malocclusion patterns. DICOM files of 432 TMJs from 216 patients (127 females, 89 males; mean ages 29.4 ± 12.6 and 31.2 ± 16.6 years, respectively) were analyzed using Dolphin Imaging software (version 11.95). Participants were grouped into two main groups: TMD (n = 199 TMJs) and control (n = 233 TMJs). Skeletal classification was based on the ANB angle to assess sagittal relationships, categorized as Class I (1°- 4°), Class II (> 4°), and Class III (< 1°). Vertical skeletal patterns were evaluated based on the SN-MP angle and classified as hypodivergent (< 27°), normodivergent (27°- 37°), and hyperdivergent (> 37°). There was no significant association observed between TMD and either gender or vertical skeletal pattern (P > .05). However, a significant relationship was found between TMD and sagittal malocclusion (P < .05). Patients in the TMD group demonstrated significantly greater anterior, lateral, and medial joint spaces (P < .05) and a more posterior condylar position. Furthermore, condylar morphology differed markedly between the TMD and control groups (P < .05). In the control group, round and oval condylar shapes were most common in the coronal and sagittal views, respectively. In contrast, the TMD group more frequently exhibited angled, finger-shaped condyles. TMJ morphological and morphometric alterations are significantly associated with TMD and may vary across different sagittal skeletal malocclusion patterns.

PMID 42463713
Read full article →
PubMedScientific reports2026-07-17

High resolution full-length 16S rRNA gene sequencing reveals distinct fecal microbial consortium associated with colorectal cancer in Saudi Arabia.

Aldriwesh Marwh G MG, Altammami Musaad M, Alswaji Abdulrahman A AA, Almatrafi Roua R et al.

The gut microbiota has emerged as a potential biomarker in the pathogenesis of colorectal cancer (CRC). Although several studies across diverse populations have identified CRC-associated microbial signatures, evidence from the Saudi Arabian population remains scarce. In this case-control study, we profiled and compared the fecal microbiotas of Saudi patients with CRC (n = 52) with those of two control groups: healthy relatives (n = 38) and an independent healthy cohort (n = 37). Full-length 16S rRNA gene sequencing was performed using Oxford Nanopore Technology. Demographic, diet, clinical, and diagnostic data were collected and analyzed in parallel. Among 127 participants, 76 (59.8%) were female, with an overall median age of 40.5 years (IQR: 29.0-60.0) that differed significantly across cohorts (P < 0.005). Patients with CRC showed higher observed richness and lower Shannon diversity than independent healthy individuals (q < 0.05). Principal coordinates analysis based on Bray-Curtis dissimilarity showed distinct clustering in patients with CRC compared to their healthy relatives (R2 = 1.99%, BH-FDR-adjusted q = 0.027) and the independent healthy cohort (R 2= 1.71%, BH-FDR-adjusted q = 0.049). Differential abundance analysis identified Fusobacterium animalis as a CRC-specific species, undetectable in healthy cohorts. Species-level co-occurrence network analysis further demonstrated positive associations among F. animalis, Peptostreptococcus stomatis, Dialister pneumosintes, and Parvimonas micra. These anaerobes, typically recognized as oral bacteria, formed a tightly connected consortium unique to patients with CRC but absent in healthy cohorts. These results suggest a CRC-specific microbial signature with potential utility as a non-invasive biomarker for early detection. Future multi-omics studies are warranted to support the development of microbiota-based diagnostics for CRC management.

PMID 42463816
Read full article →
PubMedBMC immunology2026-07-17

Downregulated miR-1290 serves as a diagnostic and prognostic biomarker in sepsis and protects against inflammatory injury by targeting TAOK1.

Gao Daixiu D, Wang Minxin M

MicroRNAs (miRNAs) are key regulators and potential biomarkers for early diagnosis and prognosis of sepsis. To investigate the diagnostic and prognostic value, and molecular mechanism of miR-1290 in sepsis. Enrollment comprised 127 healthy controls and 133 patients with sepsis. RT‑qPCR measured serum miR-1290 and TAO Kinase 1 (TAOK1) levels. ROC curve and Logistic regression assessed diagnostic efficacy and risk prediction of miR-1290 for sepsis. Kaplan-Meier and Cox regression evaluated its short-term prognostic value. An LPS-induced macrophage (THP-1) inflammation model was established to examine the effects of miR-1290 on cell viability (CCK-8), inflammatory cytokines TNF-α, IL-6, and IL-1β (ELISA), and macrophage polarization markers (RT-qPCR). Bioinformatic prediction and dual-luciferase reporter verified the interaction between miR-1290 and TAOK1, and rescue experiments were conducted to determine that TAOK1 reverses the biological functions of miR-1290. miR-1290 was downregulated in patients with sepsis and showed high diagnostic value. Its expression level was negatively correlated with both SOFA and APACHE II scores, and demonstrated good predictive performance for short-term mortality. In the LPS-induced macrophage model, overexpression of miR-1290 suppressed TAOK1 expression, elevated cell viability, suppressed the secretion of TNF-α, IL-6, and IL-1β, inhibited M1 polarization (downregulation of iNOS and CD86), and enhanced M2 polarization (upregulation of CD206 and Arg-1). Moreover, TAOK1 overexpression reversed the anti-inflammatory and protective effects of miR-1290. Downregulated miR-1290 shows potential as both a diagnostic and prognostic indicator in sepsis. It may exert a protective effect on macrophages by targeting TAOK1, thereby inhibiting disease progression.

PMID 42464104
Read full article →
PubMedTherapeutic advances in psychopharmacology2026-07-17

Patterns of antidepressant treatment changes among adults with major depressive disorder in Northwest Ethiopia: a hospital-based cross-sectional study.

Moges Tilaye Arega TA, Tamene Fasil Bayafers FB, Zewdu Woretaw Sisay WS, Tarekegn Getachew Yitayew GY et al.

Major depressive disorder (MDD) is a prominent cause of worldwide disability, severely affecting quality of life in Ethiopia. Despite a significant prevalence of treatment-resistant depression, challenges in treatment adherence, and a high prevalence of adverse drug reactions, the studies in Ethiopia have limited data on antidepressant treatment changes. This research aims to identify patterns of antidepressant treatment changes, the reasons for treatment changes, and associated factors among patients with MDD in Ethiopia. A hospital-based cross-sectional study. The present study was conducted at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia, from June 01, 2025, to August 30, 2025. The data was entered, cleaned, and analyzed by using SPSS Version 27. The antidepressant side-effect checklist was used to classify adverse effects as mild, moderate, or severe. The Naranjo adverse drug reactions (ADRs) probability scale assessed antidepressant-related adverse drug reactions; non-adherence was evaluated using a self-reported tablet count tool. A multivariable logistic regression model was utilized to identify factors associated with antidepressant treatment changes. The significance level was set at a p-value of 0.05, with a 95% confidence interval (CI). Out of 220 respondents, 127 (57.7%) did not respond to their antidepressants, which impacted their ability to carry out daily responsibilities. Approximately one-third of participants (80, or 36.4%) had switched medications. More than half of the patients with MDD (114, or 51.82%) experienced ADRs related to antidepressants. The prevalence of non-adherence to medication was 54.6%; 95% CI: 48.6, 60.9. Antidepressant treatment change was significantly associated with having a history of relapse (AOR = 2.52, 95% CI: 1.28, 5.42) and a history of hospital admission (AOR = 2.35, 95% CI: 1.25, 7.59). The management of MDD in Ethiopia faces challenges such as high non-adherence rates, significant ADRs, and limited access to alternative treatments. About 36.4% of patients underwent antidepressant treatment changes. A history of relapse and admission history were associated with antidepressant treatment changes. Future research should investigate longitudinal research to understand non-response and its impact on patient outcomes.

PMID 42465695
Read full article →
PubMedBMJ public health2026-07-17

Clinical features, risk factors and 28-day mortality in neonates with carbapenem-resistant sepsis or meningitis in a South African tertiary neonatal unit: a prospective cohort study.

Thomas Reenu R, Sharland Michael M, Clements Michelle M, Velaphi Sithembiso Christopher SC

Carbapenem-resistant, Gram-negative bacteria (GNB) are a significant cause of neonatal sepsis, threatening survival. There is a scarcity of robust data on their burden and outcomes in low- and middle-income countries (LMICs). We aimed to describe clinical and microbiological characteristics, outcomes and mortality risk factors in neonates infected with GNB and assess the impact of carbapenem resistance. Prospective observational cohort study from 1 February 2021 to 30 June 2023 conducted in a tertiary neonatal unit in Johannesburg, South Africa, in infants <90 days with culture-confirmed blood or cerebrospinal fluid infection with GNB. The primary outcome was mortality by day-28 post-sepsis diagnosis. Gram-negative sepsis incidence was 6.6/1000 patient-days. Among 353 infants enrolled (median birth weight 1465 g; gestational age 31 weeks), 173 (49%) had carbapenem-sensitive organisms (CSO), 152 (43%) had carbapenem-resistant organisms (CRO) and susceptibility was not reported in 28 (8%). There were 404 GNB isolated. Acinetobacter baumannii (156/404; 39%) and Klebsiella pneumoniae (127/404; 31%) were predominant. Of the 34 infants with early-onset sepsis caused by GNB, 13 (38%) were infected with CRO. Day-28 all-cause mortality was 23%. Infections with CRO were associated with higher crude 28-day mortality (31% vs 17%; OR 2.22, 95% CI 1.32 to 3.75; p=0.003), though this was not an independent association (p=0.552). Independent factors associated with mortality were the need for inotropes (adjusted OR (aOR) 6.09; 95% CI 3.05 to 12.15; p<0.001), metabolic acidosis (aOR 5.43, 95% CI 2.11 to 14.02; p<0.001), lethargy (aOR 3.20, 95% CI 1.46 to 7.02; p=0.004), glucose instability (aOR 2.31, 95% CI 1.22 to 4.36; p=0.010) and positive culture with A. baumannii (aOR 4.57, 95% CI 2.00 to 10.41; p<0.001) and K. pneumoniae (aOR 2.77, 95% CI 1.18 to 6.48; p=0.017). There is a substantial burden of Gram-negative neonatal infections, particularly due to CRO, exceeding rates reported in other LMICs in Africa and globally. Although carbapenem resistance was not independently associated with mortality, infants with CRO had approximately two times higher crude mortality compared with those with CSO, emphasising the urgent need for antimicrobial stewardship and infection prevention interventions. Neonatal-specific trials are needed addressing prevention and optimal antibiotic treatment of CRO infections to improve outcomes.

PMID 42466448
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about NIK-127